Speakers

Louis Boon

JJP Biologics

CSO and Management Board Member

About Louis Boon

Louis Boon has over 25 years of experience in the discovery and development of novel antibody therapeutics and is the inventor behind over 20 patent applications of biologics across different disease areas. He is also a thought leader in molecular and cellular immunology, having co-authored over 320 publications in international scientific journals in the field of medical biotechnology. His passion to develop and deliver safe and effective medicines to patients has led him to take the role of CSO at Polpharma Biologics Utrecht, where he is responsible for their innovative antibody pipeline and takes lead on their development of high-producing cell lines and CMC development.

Louis obtained his Ph.D. in Biochemistry at the University of Amsterdam. He was founder of various companies focused around the generation and development therapeutic monoclonal antibodies, primarily in the field of cancer and inflammation. In 2003, he was one of the founders of Bioceros BV, now Polpharma Biologics, where he currently holds the position of Principle Scientific Advisor. In addition, he held positions as CSO for MacroZyme BV, 4AZA Bioscience NV, FF Pharma and VP preclinical for PanGenetics BV and Tanox.

JJP Biologics

Generating new and novel biologics

JJP Biologics is an innovative Polish biotechnology company developing novel biological therapeutics around established companion diagnostics. They are part of the growing Polish biotechnology sector, led by some of the biggest names in the industry and backed by the Starak family.

Research and innovation is the bedrock of their business. JJP Biologics advances leading-edge science through a dynamic and collaborative approach. This enables them to find better solutions for treating the world’s most challenging diseases. They focus on discovering, developing and delivering drugs in therapeutic areas where they have proven expertise—and can make an impact. This is mainly focused around immunology, inflammation and oncology.

Visit the website of JJP Biologics